Raymond James & Associates Sells 4,403 Shares of STAAR Surgical (NASDAQ:STAA)

Raymond James & Associates trimmed its position in shares of STAAR Surgical (NASDAQ:STAA) by 25.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 12,696 shares of the medical instruments supplier’s stock after selling 4,403 shares during the quarter. Raymond James & Associates’ holdings in STAAR Surgical were worth $667,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Metropolitan Life Insurance Co NY boosted its position in STAAR Surgical by 6.4% during the 4th quarter. Metropolitan Life Insurance Co NY now owns 3,052 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 184 shares in the last quarter. Sei Investments Co. boosted its position in STAAR Surgical by 0.6% during the 2nd quarter. Sei Investments Co. now owns 34,969 shares of the medical instruments supplier’s stock valued at $2,484,000 after acquiring an additional 195 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in STAAR Surgical by 18.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,287 shares of the medical instruments supplier’s stock valued at $102,000 after acquiring an additional 202 shares in the last quarter. Rockefeller Capital Management L.P. boosted its position in STAAR Surgical by 10.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,123 shares of the medical instruments supplier’s stock valued at $103,000 after acquiring an additional 205 shares in the last quarter. Finally, Legacy Advisors LLC boosted its position in STAAR Surgical by 5.0% during the 2nd quarter. Legacy Advisors LLC now owns 5,650 shares of the medical instruments supplier’s stock valued at $297,000 after acquiring an additional 268 shares in the last quarter. 96.70% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Mizuho reaffirmed a “buy” rating and set a $65.00 price objective on shares of STAAR Surgical in a research report on Wednesday, September 13th. StockNews.com raised STAAR Surgical from a “sell” rating to a “hold” rating in a research report on Friday. Stifel Nicolaus dropped their price target on STAAR Surgical from $45.00 to $40.00 and set a “hold” rating on the stock in a research report on Friday, September 22nd. Canaccord Genuity Group reissued a “hold” rating and issued a $48.00 price target (down from $77.00) on shares of STAAR Surgical in a research report on Thursday, August 3rd. Finally, Piper Sandler dropped their price target on STAAR Surgical from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, November 2nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $54.33.

STAAR Surgical Stock Down 8.8 %

Shares of NASDAQ STAA opened at $34.50 on Tuesday. STAAR Surgical has a twelve month low of $33.76 and a twelve month high of $81.81. The firm has a market cap of $1.67 billion, a P/E ratio of 88.46 and a beta of 1.05. The company has a 50 day moving average of $41.16 and a 200 day moving average of $50.20.

Insider Buying and Selling

In related news, Director Elizabeth Yeu Lin bought 2,500 shares of the firm’s stock in a transaction on Thursday, September 21st. The stock was acquired at an average cost of $40.00 per share, for a total transaction of $100,000.00. Following the purchase, the director now owns 2,855 shares in the company, valued at $114,200. The acquisition was disclosed in a filing with the SEC, which is available through this link. In related news, major shareholder Broadwood Partners, L.P. bought 60,874 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was acquired at an average cost of $41.26 per share, for a total transaction of $2,511,661.24. Following the purchase, the insider now owns 8,973,044 shares in the company, valued at $370,227,795.44. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Elizabeth Yeu Lin bought 2,500 shares of the firm’s stock in a transaction on Thursday, September 21st. The shares were bought at an average price of $40.00 per share, with a total value of $100,000.00. Following the completion of the purchase, the director now owns 2,855 shares in the company, valued at approximately $114,200. The disclosure for this purchase can be found here. Insiders bought a total of 659,278 shares of company stock worth $24,616,465 in the last three months. Insiders own 1.10% of the company’s stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.